A capillary hemangioma is the most common benign tumor of infancy, built from densely packed, rapidly multiplying tiny blood vessels. Most appear within the first few weeks of life, grow quickly for several months, then slowly shrink on their own over years. The term itself is a bit old-fashioned and can cause confusion, since it overlaps with the modern clinical name “infantile hemangioma” and also gets applied to a very different growth that appears in adults. For most families, the practical question is straightforward: will this go away, and does it need treatment?
Who Gets Them and Why
Capillary hemangiomas show up in roughly four to five percent of infants, making them far more common than most parents expect. A large meta-analysis of risk factors found that girls are about twice as likely to develop one as boys. Low birth weight carried the strongest association, with affected infants more than four times as likely to have a hemangioma. Premature birth, multiple gestations such as twins, a family history of hemangiomas, and maternal progesterone therapy during pregnancy all roughly doubled the odds.1PubMed. Risk factors for infantile hemangioma: a meta-analysis Placental abnormalities have also been implicated as a separate risk factor.2PubMed Central. Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment
No one has pinpointed a single cause. The leading theory is that something goes wrong in the signaling between blood vessel cells and their growth regulators during fetal or early postnatal development. Multiple molecular pathways have been identified as players, including those that control new blood vessel formation, oxygen sensing, and cell survival.3PubMed Central. Signaling pathways in the development of infantile hemangioma One intriguing line of research found that infantile hemangioma tissue shares a closer gene-expression profile with human placenta than with any other tissue tested, leading to the hypothesis that these tumors may originate from displaced placental cells.4PubMed Central. Evidence by molecular profiling for a placental origin of infantile hemangioma
How They Grow and Fade
Capillary hemangiomas follow a predictable three-phase life cycle. The first phase, called the proliferating phase, is marked by rapid growth during roughly the first year of life. During this window, the tiny vessels multiply aggressively, driven by high levels of growth signals like vascular endothelial growth factor (VEGF). The second phase, involution, begins sometime around the first birthday and stretches over the next one to five years. During involution, a natural brake kicks in: the tissue starts producing inhibitors of new vessel formation, the cell turnover slows, and the hemangioma gradually shrinks and pales. A third and final phase, the involuted phase, brings continued improvement out to roughly age six to twelve, though many hemangiomas look substantially faded well before then.5PubMed Central. Cellular markers that distinguish the phases of hemangioma during infancy and childhood
Not every hemangioma resolves to completely normal-looking skin. After involution, some leave behind residual changes: a patch of loose or slightly wrinkled skin, a faint discoloration, visible tiny vessels on the surface, or a small fatty lump where the tumor once sat. The bigger and deeper the original hemangioma, the more likely it is to leave a visible trace.
When Treatment Is Needed
Because most capillary hemangiomas resolve on their own, the default approach for small, uncomplicated ones is careful observation. Treatment enters the picture when a hemangioma threatens a vital function, causes pain, or is heading toward permanent disfigurement. The most common triggers for intervention include hemangiomas that obstruct the airway, block an infant’s vision, grow on the lip or nose in a way that distorts feeding or breathing, or ulcerate repeatedly.
Oral propranolol, a beta-blocker originally used for heart conditions, has become the first-line medical treatment for problematic infantile hemangiomas. Researchers believe it works through a combination of mechanisms: constricting the abnormal vessels (which is why the color often fades within days of starting), dialing down the production of growth factors like VEGF, and triggering programmed cell death in the endothelial cells lining the vessels.6Actas Dermo-Sifiliográficas. Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations Treatment typically starts in the first few months of life and continues for several months to over a year, depending on the response.
For shallow, surface-level hemangiomas that do not pose a functional threat but are cosmetically concerning, topical timolol (another beta-blocker applied as drops or gel directly on the skin) is an alternative. A retrospective study found it was safe and effective for superficial hemangiomas up to ten centimeters across, with the best outcomes in infants treated before three months of age or with lesions under five centimeters.7PubMed Central. The timing and safety of topical timolol treatment for superficial infantile hemangioma: a retrospective cohort study The evidence is somewhat mixed, though. A randomized trial comparing topical timolol to a placebo found no significant difference in complete resolution at 24 weeks, although timolol did produce an early improvement in the hemangioma’s color and was well tolerated with no systemic side effects.8PubMed Central. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial This suggests topical timolol may help with appearance earlier than doing nothing would, but its ability to meaningfully change the final outcome remains uncertain.
Ulceration and Pain
Ulceration is the single most common complication of infantile hemangiomas. When the rapidly growing surface breaks down, it creates an open wound that bleeds easily, hurts, and is prone to infection and scarring. Managing these ulcers can be frustrating. An audit of over 350 medical records at a children’s hospital found that among the 84 patients with ulcerated hemangiomas, wound healing took an average of 105 days and required roughly five outpatient visits. A wide variety of dressings were used, but no single type proved clearly superior to another.9PubMed Central. Wound management of ulcerated haemangioma of infancy – an audit
A systematic review of treatments for ulcerated hemangiomas found that oral propranolol led to complete healing in about 97 percent of treated cases, making it the most consistently effective option. Corticosteroids, on the other hand, had a substantial failure rate, with many patients needing to switch to another therapy. Surgical removal was generally reserved for larger ulcerated hemangiomas or those causing other complications.10PubMed. Medical, Surgical, and Wound Care Management of Ulcerated Infantile Hemangiomas: A Systematic Review Topical timolol has also shown promise in individual cases, with one report describing complete healing of an ulcerated hemangioma within a month of starting treatment.11PubMed Central. Efficacious Healing of Ulcerated Infantile Hemangiomas Using Topical Timolol
Hemangiomas Near the Eye
A capillary hemangioma sitting on or near the eyelid deserves close attention because it can interfere with normal visual development. Even moderate pressure on the developing eye can warp the cornea and cause astigmatism, and if the hemangioma blocks the visual axis, the brain may start ignoring input from that eye altogether, a condition called amblyopia (sometimes known as “lazy eye”). A study of 43 children with periocular hemangiomas found that roughly one in five developed amblyopia. In nearly all of those cases, the hemangioma sat on the upper eyelid of the affected eye, and most had significant astigmatism at diagnosis.12JAMA Ophthalmology. Rate of Amblyopia in Periocular Infantile Hemangiomas
This is one situation where “wait and see” carries real risk. Once amblyopia sets in during the critical window of visual development in infancy and early childhood, reversing it becomes much harder. That is why periocular hemangiomas are among the strongest indications for early medical treatment, usually oral propranolol. Before beta-blockers became the standard, intralesional corticosteroid injections were a mainstay for eyelid hemangiomas and were considered a safe and effective option.13PubMed. Intralesional corticosteroid injections for infantile hemangiomas of the eyelid Steroids have largely been replaced by propranolol but remain in use in some settings, particularly where cost is a concern.14Journal of Pediatric Surgery. Management of childhood hemangioma: A review of 2398 cases
Large Facial Hemangiomas and PHACE Syndrome
When a hemangioma covers a large area of the face, especially spanning more than one facial region, doctors screen for a condition known as PHACE syndrome. PHACE is an acronym for a cluster of anomalies that can accompany large facial hemangiomas: abnormalities of the brain’s blood vessels, heart defects, eye problems, and sometimes sternal or abdominal abnormalities. In a study of 108 infants with large facial hemangiomas, about 31 percent met the criteria for PHACE. The risk was highest in those with the largest hemangiomas and those spanning multiple facial areas. The most frequently observed problems were in the arteries supplying the brain, found in 91 percent of PHACE patients, followed by heart defects in 67 percent.15Pediatrics. Risk for PHACE Syndrome in Infants With Large Facial Hemangiomas
A consensus statement defines the diagnostic threshold: a “definite” PHACE diagnosis requires a segmental facial hemangioma or one larger than five centimeters plus at least one major associated finding or two minor ones.16Pediatrics. Consensus Statement on Diagnostic Criteria for PHACE Syndrome This means that not every big facial hemangioma leads to PHACE, but the screening is important enough that imaging of the brain and heart is routine for infants who fit the profile. Upper face hemangiomas, particularly those over the forehead and temple, carry the strongest association.
Lasers and Surgery
Pulsed dye laser therapy targets the red color of hemoglobin inside the hemangioma’s vessels. An early study of ten children treated with pulsed dye laser reported an average regression of about 70 percent after roughly three sessions, with no scarring, ulceration, or other adverse effects.17JAMA Dermatology. Capillary Hemangiomas and Treatment with the Flash Lamp-Pumped Pulsed Dye Laser In current practice, the laser’s role has shifted. One comparative study concluded that pulsed dye laser should be considered mainly as a treatment option during the first six months when parents are concerned about cosmetic outcome, and that its greatest value lies in treating residual surface redness and telangiectasias that persist after the hemangioma has involuted.18PubMed. Superficial hemangioma: pulsed dye laser versus wait-and-see
Surgical excision is generally reserved for hemangiomas that do not respond adequately to medication, that leave behind disfiguring skin changes after involution, or that cause complications like bleeding or airway obstruction that demand immediate resolution. Surgery is typically deferred until after the proliferating phase when possible, because operating on a rapidly growing vascular tumor carries higher risks of bleeding and incomplete removal.
How Doctors Tell Them Apart from Other Vascular Growths
Terminology in this field has been a longstanding source of confusion. The modern classification system divides vascular anomalies into two broad camps: vascular tumors (which involve abnormal cell growth) and vascular malformations (which are structural defects in vessels that the child is born with and that grow proportionally without the proliferative burst that characterizes a hemangioma).19PubMed Central. Updated Classification of Vascular Anomalies Capillary hemangiomas fall squarely in the tumor category, even though the word “tumor” alarms parents. They are benign growths of endothelial cells, not cancers.
When the diagnosis is unclear on clinical grounds alone, a tissue marker called GLUT1 (a glucose transporter protein) is the key differentiator. Infantile hemangiomas are the only vascular lesions that stain positive for GLUT1. In a pooled review, about 95 percent of infantile hemangiomas tested positive, while every type of vascular malformation tested negative.20PubMed. The utility of GLUT1 as a diagnostic marker in cutaneous vascular anomalies: A review of literature and recommendations for daily practice This makes GLUT1 extremely useful when a biopsy is needed to settle whether a lesion is a true hemangioma or something else entirely, such as a venous malformation or a congenital hemangioma (a related but distinct tumor that is present at full size at birth and behaves differently).21Journal of Plastic, Reconstructive & Aesthetic Surgery. The use of GLUT-1 as a diagnostic marker in vascular lesions
For deeper lesions not visible on the surface, imaging helps. MRI of intramuscular capillary-type hemangiomas typically shows a well-defined soft-tissue mass with signs of fast blood flow, and Doppler ultrasound reveals a mass with enlarged feeding arteries.22PubMed. Intramuscular capillary-type hemangioma: radiologic-pathologic correlation
A Common Misconception About Dangerous Bleeding
Parents who search for capillary hemangiomas online will sometimes encounter alarming descriptions of Kasabach-Merritt phenomenon, a life-threatening condition in which a vascular tumor traps and destroys platelets, leading to severe bleeding and clotting problems. Despite decades of medical literature linking this to “capillary hemangiomas,” the association turns out to be a case of mistaken identity. Research has established that the vascular lesions behind Kasabach-Merritt phenomenon are not true infantile hemangiomas at all. They are a different category of tumor, specifically kaposiform hemangioendothelioma or tufted angioma, both of which look different under the microscope and behave differently clinically.23The Journal of Pediatrics. Kasabach-Merritt phenomenon is a tufted angioma or kaposiform hemangioendothelioma not a true capillary hemangioma The confusion arose because older naming conventions lumped several vascular tumors under the same umbrella. If your child has a classic infantile hemangioma, Kasabach-Merritt phenomenon is not a concern.
Molecular Signals That Drive Growth
The Notch signaling pathway, a communication system cells use to coordinate growth and differentiation, appears to play a significant role in hemangioma biology. Studies have found that all four Notch receptors and key Notch ligands are expressed in hemangioma tissue.24PubMed Central. A potential role for notch signaling in the pathogenesis and regulation of hemangiomas More telling is the pattern: Notch activity is significantly higher in proliferating hemangiomas than in involuted ones or those treated with propranolol, suggesting that this signaling pathway helps fuel the growth phase.25Journal of Vascular Surgery: Venous and Lymphatic Disorders. NOTCH pathway activation in infantile hemangiomas Genome-wide profiling has confirmed that specific Notch components like Jagged 1 and Notch 4 are dramatically upregulated in proliferating tissue compared to normal placental tissue.26The American Journal of Pathology. Identification of Signaling Systems in Proliferating and Involuting Phase Infantile Hemangiomas by Genome-Wide Transcriptional Profiling This research has not yet translated into targeted therapies, but it helps explain why propranolol works: the drug appears to dampen several of these overactive signaling pathways simultaneously.
The Emotional Toll on Families
A hemangioma on a child’s face can affect far more than the skin. Research into the psychosocial impact has consistently found that parents experience strong emotional reactions, particularly during the growth phase when the hemangioma is at its most prominent. Feelings of disbelief, fear, and grief are common, and encounters with strangers who stare, comment, or even accuse parents of child abuse add a layer of social stress.27PubMed. Growing up with a facial hemangioma: parent and child coping and adaptation About half of parents in one study expressed significant dissatisfaction with their medical care, often related to being told simply to wait for the hemangioma to go away without acknowledgment of its emotional weight.
For children themselves, the picture is mixed. A survey of over 200 families found that the majority of parents and children were not negatively affected in their overall quality of life, but the story changed for older children and those with visible or complicated hemangiomas. Children aged eight to eleven were reported by parents to have more negative emotions, and children with visible hemangiomas were more likely to agree that their life would have been different without one.28PubMed. Health-related quality of life and impact of haemangiomas on children and their parents Separate research found that preschool-age children with facial hemangiomas felt more negatively valued by others than their peers.29JAMA Otolaryngology–Head & Neck Surgery. Social Impact of Facial Infantile Hemangiomas in Preteen Children These findings argue that dismissing a facial hemangioma as “just cosmetic” misses the point. Early treatment, when it can safely reduce the size or redness of a prominent lesion, may matter for reasons that go well beyond skin.
Capillary Hemangiomas in Adults
When the term “capillary hemangioma” comes up in an adult, it almost always refers to a lobular capillary hemangioma, sometimes better known as a pyogenic granuloma. These are a completely different entity from the infantile version. They are small, rapidly growing nodules made of tiny capillary-sized lobules lined by plump endothelial cells, and they tend to crop up over weeks to months rather than being present from birth. A study of 16 adults with periocular lobular capillary hemangiomas found a median age at diagnosis of 38 years, with the most common location being the eyelid, followed by the conjunctiva. The median tumor diameter was just six millimeters, and all were treated successfully with surgical removal, with recurrence in only one case.30PubMed Central. Periocular Lobular Capillary Hemangioma in Adults: A Clinicopathological Study
Occasionally, a true acquired capillary hemangioma that resembles the infantile type histologically will appear in a young adult. One reported case involved an 18-year-old woman with a slow-growing eyelid mass that had been present for nine years and was confirmed on biopsy as an acquired capillary hemangioma.31Annals of the National Academy of Medical Sciences (India). Acquired eyelid capillary hemangioma in a young adult: Clinical, surgical, and histopathological correlation Cases like this are rare enough to warrant case reports, which underscores how unusual it is outside infancy. For adults, surgical removal is typically straightforward and curative, and the natural involution seen in babies does not apply.
Hepatic Hemangiomas and Internal Involvement
Capillary hemangiomas can occasionally grow in internal organs, with the liver being the most clinically significant site. Most hepatic hemangiomas in adults are small, incidentally discovered on imaging, and require no treatment. In rare cases, however, a large hepatic hemangioma can create enough abnormal blood flow to cause high-output heart failure, a condition in which the heart is forced to pump harder than normal because blood is being shunted through the tumor’s vast network of tiny vessels.32PubMed. High-Output Heart Failure from a Hepatic Hemangioma With Exertion-Induced Hypoxia In infants, multiple liver hemangiomas sometimes appear alongside cutaneous ones and may require systemic treatment. The vast majority of liver hemangiomas, though, are benign curiosities that show up on a scan done for an unrelated reason and never cause symptoms.